GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
Read Next
- NZD/USD Under Pressure Amidst USD Strength :: InvestMacro
- Bitcoin (BTC) Surges to New Heights Amidst Robust Capital Inflows
- LIC losses nearly Rs 9000 crore; PSBs witness fall, ET BFSI
- People who become easier to manipulate as they get older typically display these 8 behaviors (without realizing it)
- CFPB expands oversight of Apple Pay, other digital payments services
- LiquidityBook completes SOC 1 Type 1 and SOC 2 Type 1 audits
- Harnessing AI for Neuroscience: IIT Madras and NVIDIA’s Innovative Approach
